## Seminar in Epileptology

Epileptic Disord 2020; 22 (3): 252-63

# How to diagnose and treat post-stroke seizures and epilepsy

Johan Zelano <sup>1,2</sup>, Martin Holtkamp <sup>3</sup>, Nivedita Agarwal <sup>4</sup>, Simona Lattanzi <sup>5</sup>, Eugen Trinka <sup>6,7,8</sup>, Francesco Brigo <sup>9</sup>



<sup>&</sup>lt;sup>1</sup> Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden

<sup>&</sup>lt;sup>2</sup> Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden

<sup>&</sup>lt;sup>3</sup> Epilepsy-Center Berlin-Brandenburg, Department of Neurology, Charité -

Universitätsmedizin Berlin, Germany

<sup>&</sup>lt;sup>4</sup> Radiology Unit, Hospital of Rovereto, Trento, Italy

Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy

<sup>&</sup>lt;sup>6</sup> Department of Neurology, Christian Doppler Klinik, Paracelsus Medical University, Affiliated partner ERN EpiCARE, Salzburg, Austria

Center for Cognitive Neuroscience, Salzburg, Austria

<sup>&</sup>lt;sup>8</sup> Public Health, Health Services Research and HTA, University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria

Department of Neurology, Franz Tappeiner Hospital, Merano, Italy







COW RISK OF SEIZURE RECURRENCE ~30% in the following 10 years

33.0% (95% CI: 20.7-49.9%)

\*70% in the following 10 years

71.5% (95% CI: 59.7-81.9%)

Hesdorffer et al., Epilepsia. 2009;50:1102-8

### **POST-STROKE EPILEPSY**

One unprovoked seizure and a probability of further seizures of at least 60% over the next 10 years



# TREATMENT OF POST-STROKE EPILEPSY: EVIDENCE FROM THE LITERATURE

	Evaluated AEDs	No. of patients	Main findings
Randomised, open-label trials			
Gilad R et al., 2007 <sup>1</sup>	LTG vs CBZ-CR	64	<ul><li>No difference in efficacy</li><li>LTG better tolerated</li></ul>
Consoli D et al., 2012 <sup>2</sup>	LEV vs CBZ-CR	106	<ul><li>No difference in efficacy</li><li>LEV better tolerated</li></ul>
Uncontrolled studies			
Alvarez-Sabín J et al., 2002 <sup>3</sup>	GBP	71	Good efficacy and tolerability
Belcastro V et al., 20084	LEV	35	Good efficacy and tolerability
Kutlu G et al., 2008 <sup>5</sup>	LEV	34	Good efficacy and tolerability
Huang YH et al., 2015 <sup>6</sup>	PHT, VPA, CBZ, different new AEDs	3,622	VPA and new AEDs more effective than PHT

AED, antiepileptic drug; CBZ, carbamazepine; CBZ-CR, controlled-release carbamazepine; GBP, gabapentin; LEV, levetiracetam; LTG, lamotrigine; PHT, phenytoin; VPA, valproate.



<sup>1.</sup> Gilad R et al. Clin Neuropharmacol 2007; 30(4): 189-195; 2. Consoli D et al. Cerebrovasc Dis 2012; 34(4): 282-289; 3. Alvarez-Sabín J et al. Neurology 2002; 59(12): 1991-1993; 4. Belcastro V et al. Epilepsy Res 2008; 82(2-3): 223-226; 5. Kutlu G et al. Epilepsy Behav 2008; 13(3): 542-544; 6. Huang YH et al. Eur J Neurol 2015; 22(11): 1459-1468

# TREATMENT OF POST-STROKE EPILEPSY: PRACTICAL SUGGESTIONS

- There are no strong evidence-based recommendations
- Choices should rely mostly on:
  - RCTs conducted in elderly patients with focal epilepsy of various aetiologies (LEV, LTG, VPA, LCM)
  - Individual considerations
- Tolerability is a major issue (perhaps more critical than efficacy!):
  - Vulnerability of elderly patients to the adverse effects of drugs ("start low and go slow")
  - Consider comorbid conditions and use of other drugs (drug interactions)
  - Consider renal or hepatic impairment for dose adjustment
  - Risk of impaired recovery after stroke with some drugs (phenytoin, phenobarbital, benzodiazepines)
- Pharmacokinetic interactions are a major issue: preferential use of non-enzyme inducing/inhibiting drugs
- Consider the need for rapid titration (LCM or LEV preferable over LTG)

